BHVN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

12.285

Open

12.120

VWAP

12.00

Vol

2.00M

Mkt Cap

2.00B

Low

11.530

Amount

22.00M

EV/EBITDA(TTM)

--

Total Shares

129.00M

EV

2.00B

EV/OCF(TTM)

--

P/S(TTM)

--

Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.

Show More

Events Timeline

(ET)

2026-01-21

16:20:00

Dow Jones Rises 588.64 Points as Trump Discusses Greenland

2026-01-21

12:10:00

Major Averages Bounce Back at Noon, Dow Up 288.53 Points

2025-12-26 (ET)

2025-12-26

16:10:00

Stocks Fluctuate Near All-Time Highs, S&P 500 Slightly Declines

2025-12-26

12:10:00

Nasdaq Declines as Target Faces Investor Pressure

2025-12-26

09:00:00

Futures Little Changed as Coupang Shares Rise 6%

News

an image of Benzinga

Wall Street Analysts Upgrade Ratings and Price Targets for Multiple Companies

an image of CNBC

RBC Upgrades Biohaven to Outperform on Positive Drug Data, $22 Price Target Implies 74% Upside

an image of Benzinga

Biohaven Ltd. (NYSE:BHVN) Shares Surge 3.42% to $12.10 Amid Positive Clinical Data

an image of PRnewswire

01-12PRnewswire

Biohaven Highlights Portfolio Progress at 44th Annual J.P. Morgan Healthcare Conference

an image of Newsfilter

01-12Newsfilter

Biohaven Reports Positive Clinical Results for TRAP Degrader in IgA Nephropathy Patients

an image of PRnewswire

01-07PRnewswire

Biohaven CEO Vlad Coric to Present at J.P. Morgan Healthcare Conference on January 12, 2026

14 Analyst Rating

Wall Street analysts forecast BHVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHVN is 15.09 USD with a low forecast of 9.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

6 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

9.00

Averages

15.09

High

30.00

Current: 0.000

Low

9.00

Averages

15.09

High

30.00

RBC Capital

Sector Perform -> Outperform

upgrade

$9 -> $22

AI Analysis

2026-01-21

Reason

RBC Capital

Price Target

$9 -> $22

AI Analysis

2026-01-21

upgrade

Sector Perform -> Outperform

Reason

RBC Capital upgraded Biohaven to Outperform from Sector Perform with a price target of $22, up from $9. The stock's reward/risk is "more compelling" following Biohaven's recent data, the analyst tells investors in a research note. The firm believes the data "take the worst-case scenario off the table and changes the risk profile of a key upcoming catalyst." In addition, Biohaven's degrader updates highlight the platform's potential in both Graves disease and IgA Nephropathy, contends RBC. The firm says the company's improved financial position and valuation discount relative to the platform's opportunity "creates a compelling setup" into the second half of 2026 catalysts.

Stifel

Paul Matteis

Buy

maintain

2025-12-26

Reason

Stifel

Paul Matteis

Price Target

2025-12-26

maintain

Buy

Reason

Stifel analyst Paul Matteis is reiterating a Buy rating on Xenon Pharmaceuticals (XENE) following Biohaven's (BHVN) Kv7 drug failing in a study in major depression disorder as the firm continues to believe that there's limited evidence suggesting that Biohaven's Kv7 compound BHV-7000 will be as efficacious as XEN1101. The firm, which continues to like Xenon shares heading into a pivotal 2026 with Phase 3 data for '1101 in FOS, keeps a Buy rating on Xenon shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BHVN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Biohaven Ltd (BHVN.N) is -2.51, compared to its 5-year average forward P/E of -4.29. For a more detailed relative valuation and DCF analysis to assess Biohaven Ltd 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-4.29

Current PE

-2.51

Overvalued PE

-2.61

Undervalued PE

-5.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

-3.48

Current EV/EBITDA

-3.05

Overvalued EV/EBITDA

-0.72

Undervalued EV/EBITDA

-6.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PS

64096.20

Current PS

0.00

Overvalued PS

288755.42

Undervalued PS

-160563.03

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Should I Buy ppta tomorrow

Intellectia · 77 candidates

Sector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical ResearchMarket Cap Category: smallWeek Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

Corvus Pharmaceuticals Inc

2.00B

RAPT Therapeutics Inc

2.00B

Aclaris Therapeutics Inc

479.00M

Lexicon Pharmaceuticals Inc

567.00M

CytomX Therapeutics Inc

896.00M

Vor Biopharma Inc

700.00M

Whales Holding BHVN

ARS Investment Partners, LLC

Lingotto Investment Management LLP

Cormorant Asset Management, LP

Bellevue Asset Management AG

Caption Management, LLC

Suvretta Capital Management, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Biohaven Ltd (BHVN) stock price today?

The current price of BHVN is 11.83 USD — it has decreased -2.23 % in the last trading day.

What is Biohaven Ltd (BHVN)'s business?

Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.

What is the price predicton of BHVN Stock?

Wall Street analysts forecast BHVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHVN is15.09 USD with a low forecast of 9.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Biohaven Ltd (BHVN)'s revenue for the last quarter?

Biohaven Ltd revenue for the last quarter amounts to -169.00M USD, decreased -4.93 % YoY.

What is Biohaven Ltd (BHVN)'s earnings per share (EPS) for the last quarter?

Biohaven Ltd. EPS for the last quarter amounts to -145729000.00 USD, increased 2.71 % YoY.

How many employees does Biohaven Ltd (BHVN). have?

Biohaven Ltd (BHVN) has 256 emplpoyees as of January 31 2026.

What is Biohaven Ltd (BHVN) market cap?

Today BHVN has the market capitalization of 2.00B USD.